Determinants of health-related quality of life in systemic lupus erythematosus: a monocentric, retrospective long-term observational study in Germany

被引:2
作者
Vordenbaeumen, S. [1 ,2 ]
Brinks, R.
Sander, O.
Chehab, G.
Lozitiello-Kiroudis, G.
Acar, H.
Richter, J.
Fischer-Betz, R.
Schneider, M.
机构
[1] Heinrich Heine Univ Dusseldorf, Med Fak, Poliklin & Funkt Bereich Rheumatol, Merowingerpl 1a, D-40225 Dusseldorf, Germany
[2] Heinrich Heine Univ Dusseldorf, Hiller Forschungszentrum Rheumatol, Merowingerpl 1a, D-40225 Dusseldorf, Germany
来源
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2019年 / 78卷 / 09期
关键词
Systemic lupus erythematosus; Health-related quality of life; Antimalarial agents; Glucocorticoids; SF-36; Fatigue; Physical component summary; Mental component summary; RECOMMENDATIONS;
D O I
10.1007/s00393-019-00691-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Improvement of health-related quality of life (HRQoL) is a prioritized treatment target in systemic lupus erythematosus (SLE). A retrospective chart review of patients with repeated HRQoL measurements from the outpatient department was conducted in order to better understand which factors drive HRQoL in established SLE. Of particular interest was the association between HRQoL and disease activity. Methods. The medical outcomes study short form 36 (SF-36), systemic lupus activity measure (SLAM) and routine clinical data of 169 patients (83% female, mean age 40.3 +/- 13 years, disease duration 9.4 +/- 7 years) over an average of 7.1 +/- 4.2 years were available for analysis by linear mixed modelling. Factors associated with the physical component summary (PCS) and mental component summary (MCS) of the SF-36 were assessed. The proportion of HRQoL which could be explained by the variables was estimated by marginal R-2 (mR(2)) and conditional R-2 (cR(2)). Results. At baseline, SLE patients showed a reduced HRQoL in all subscales of the SF-36 including PCS and MCS with the exception of vitality. A higher PCS over time was significantly associated with concurrent parameters, such as intake of antimalarial drugs, no glucocorticoid use, less fatigue, lower disease activity as well as to the baseline parameters of younger age and higher PCS (mR(2) 54.7%, cR(2) 59.9%). A higher MCS was associated with concurrent use of glucocorticoids and a higher baseline MCS (mR(2) 21.7%, cR(2) 25.1%). Conclusion. The use of antimalarial drugs and no glucocorticoid intake as well as low current disease activity are modifiable factors associated with a better physical HRQoL. The mental component of HRQoL was poorly represented by conventional parameters and not associated with parameters of disease activity in the present study cohort.
引用
收藏
页码:813 / 819
页数:7
相关论文
共 16 条
  • [1] Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA).: XVII.: Predictors of self-reported health-related quality of life early in the disease course
    Alarcón, GS
    McGwin, G
    Uribe, A
    Friedman, AW
    Roseman, JM
    Fessler, BJ
    Bastian, HM
    Baethge, BA
    Vilá, LM
    Reveille, JD
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (03): : 465 - 474
  • [2] What matters for lupus patients?
    Chehab, Gamal
    Carnarius, Heike
    Schneider, Matthias
    [J]. PRESSE MEDICALE, 2014, 43 (06): : E197 - E207
  • [3] Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions
    Elera-Fitzcarrald, Claudia
    Fuentes, Alejandro
    Alonso Gonzalez, Luis
    Burgos, Paula I.
    Alarcon, Graciela S.
    Ugarte-Gil, Manuel F.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (11) : 915 - 931
  • [4] 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
    Fanouriakis, Antonis
    Kostopoulou, Myrto
    Alunno, Alessia
    Aringer, Martin
    Bajema, Ingeborg
    Boletis, John N.
    Cervera, Ricard
    Doria, Andrea
    Gordon, Caroline
    Govoni, Marcello
    Houssiau, Frederic
    Jayne, David
    Kouloumas, Marios
    Kuhn, Annegret
    Larsen, Janni L.
    Lerstrom, Kirsten
    Moroni, Gabriella
    Mosca, Marta
    Schneider, Matthias
    Smolen, Josef S.
    Svenungsson, Elisabet
    Tesar, Vladimir
    Tincani, Angela
    Troldborg, Anne
    van Vollenhoven, Ronald
    Wenzel, Joerg
    Bertsias, George
    Boumpas, Dimitrios T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (06) : 736 - 745
  • [5] Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
    Furie, Richard
    Petri, Michelle A.
    Strand, Vibeke
    Gladman, Dafna D.
    Zhong, Z. John
    Freimuth, William W.
    [J]. LUPUS SCIENCE & MEDICINE, 2014, 1 (01):
  • [6] Gladman DD, 1997, J RHEUMATOL, V24, P2145
  • [7] Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life?
    Jolly, M
    Utset, TO
    [J]. LUPUS, 2004, 13 (12) : 924 - 926
  • [8] The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus
    Karlson, EW
    Daltroy, LH
    Lew, RA
    Wright, EA
    Partridge, AJ
    Fossel, AH
    Roberts, WN
    Stern, SH
    Straaton, KV
    Wacholtz, MC
    Kavanaugh, AF
    Grosflam, JM
    Liang, MH
    [J]. ARTHRITIS AND RHEUMATISM, 1997, 40 (01): : 47 - 56
  • [9] A general and simple method for obtaining R2 from generalized linear mixed-effects models
    Nakagawa, Shinichi
    Schielzeth, Holger
    [J]. METHODS IN ECOLOGY AND EVOLUTION, 2013, 4 (02): : 133 - 142
  • [10] The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With SystemicLupus Erythematosus
    Parodis, Ioannis
    Benavides, Angie H. Lopez
    Zickert, Agneta
    Pettersson, Susanne
    Moller, Sonia
    Henriksson, Elisabet Welin
    Voss, Anne
    Gunnarsson, Iva
    [J]. ARTHRITIS CARE & RESEARCH, 2019, 71 (06) : 811 - 821